Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across several cancer types, including breast, lung, gastric and colorectal cancer. In this setting, several novel anti-HER2 agents with relevant CNS activity are emerging, including tucatinib and trastuzumab deruxtecan. Both agents are already FDA-approved for treating advanced breast cancer, but are also being tested for the treatment of other HER2-driven histologies. The confirmation of their activity in other cancer types may provide histology-agnostic weapons against HER2-driven brain metastasis, possibly improving the prognosis of a wide population of cancer patients.

New anti-HER2 agents for brain metastasis: histology-agnostic weapons? / P. Tarantino, A. Prat, G. Curigliano. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 185:3(2021), pp. 879-881. [10.1007/s10549-020-05982-y]

New anti-HER2 agents for brain metastasis: histology-agnostic weapons?

G. Curigliano
Conceptualization
2021

Abstract

Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across several cancer types, including breast, lung, gastric and colorectal cancer. In this setting, several novel anti-HER2 agents with relevant CNS activity are emerging, including tucatinib and trastuzumab deruxtecan. Both agents are already FDA-approved for treating advanced breast cancer, but are also being tested for the treatment of other HER2-driven histologies. The confirmation of their activity in other cancer types may provide histology-agnostic weapons against HER2-driven brain metastasis, possibly improving the prognosis of a wide population of cancer patients.
Antibody–drug conjugates; Brain metastasis; HER2; Histology-agnostic; Trastuzumab deruxtecan; Tucatinib
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Tarantino2021_Article_NewAnti-HER2AgentsForBrainMeta.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 343.23 kB
Formato Adobe PDF
343.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824894
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact